FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, specifically to oncology, and can be used to treat early stage cancer with overexpression/amplification of HER-2/neu. To this end, after completing one year of adjuvant therapy with trastuzumab, the patient is administered neratinib. Neratinib is administered to the patient for a period of twelve months at a daily dose of 240 mg. Neratinib administration begins more than 2 weeks and less than four years after the last dose of trastuzumab. Method of increasing the survival of a patient without signs of disease, and a method of treatment for increasing survival without signs of invasive disease are also disclosed.
EFFECT: group of inventions provides treatment of early stage cancer with overexpression/amplification of HER-2/neu in a patient.
16 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT REGIMEN FOR BREAST CANCER USING NERATINIB | 2019 |
|
RU2804713C2 |
| ANTINEOPLASTIC COMBINATIONS OF 4-ANILINO-3-CYANOQUINOLINES AND CAPECITABINE | 2009 |
|
RU2498804C2 |
| METHODS OF TREATING EARLY BREAST CANCER WITH TRASTUZUMAB-MCC-DM1 AND PERTUZUMAB | 2015 |
|
RU2725093C2 |
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2009 |
|
RU2492860C2 |
| ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE | 2013 |
|
RU2670974C2 |
| IDENTIFICATION OF PATIENTS IN NEED OF COMBINED THERAPY WITH PD-L1 INHIBITOR | 2013 |
|
RU2692773C2 |
| COMBINATION THERAPY WITH SEMAFORIN 4D (SEMA4D) BLOCKING AND DC1 THERAPY | 2020 |
|
RU2801828C2 |
| DUOCARMICIN ADC SHOWING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2689779C2 |
| METHOD OF TREATING GEFITINIB-RESISTANT CANCER | 2006 |
|
RU2405566C9 |
| DUOCARMYCIN ADCs EXHIBITING IMPROVED ANTI-TUMOUR ACTIVITY IN VIVO | 2015 |
|
RU2769700C2 |
